P. Furet

发表

Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones.

P. Traxler, J. Green, H. Mett, 1999, Journal of medicinal chemistry.

Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.

P. Furet, N. Lydon, P. Traxler, 1997, Journal of medicinal chemistry.

4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.

P. Furet, N. Lydon, P. Traxler, 1996, Journal of medicinal chemistry.

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

G. Martiny-Baron, K. Altmann, R. Cozens, 2000, Journal of medicinal chemistry.

Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives.

S. Whitebread, P. Furet, S. Stutz, 1991, Journal of medicinal chemistry.

S-adenosylmethionine decarboxylase inhibitors: new aryl and heteroaryl analogues of methylglyoxal bis(guanylhydrazone).

P. Furet, H. Mett, P. Furet, 1993, Journal of medicinal chemistry.

Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series

Steven Whitebread, Marc de Gasparo, S. Whitebread, 1994 .

Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2.

D. Fabbro, P. Furet, T. Meyer, 1995, European journal of biochemistry.

4-Amidinoindan-1-one 2'-amidinohydrazone: a new potent and selective inhibitor of S-Adenosylmethionine decarboxylase.

P. Furet, H. Mett, P. Furet, 1993, Journal of medicinal chemistry.

Structure-activity relationships and binding model of novel aromatase inhibitors

P. Furet, M. Lang, A. Bhatnagar, 1993, The Journal of Steroid Biochemistry and Molecular Biology.

2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors.

P. Furet, P. Imbach, H. Mett, 1999, Bioorganic & medicinal chemistry letters.

Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase.

N. Lydon, H. Mett, P. Furet, 1994, Journal of medicinal chemistry.

Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds.

P. Furet, P. Furet, M. Lang, 1993, Journal of medicinal chemistry.

Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.

N. Lydon, P. Traxler, H. Mett, 1997, Journal de pharmacie de Belgique.

Inhibitors of Protein Kinases and Protein Phosphates Contributors

L. Meijer, D. Fabbro, M. Yacoub, 2005 .